HC Wainwright & Co. Initiates Coverage On ANI Pharmaceuticals with Buy Rating, Announces Price Target of $50
HC Wainwright & Co. analyst Oren Livnat initiates coverage on ANI Pharmaceuticals (NASDAQ:ANIP) with a Buy rating and announces Price Target of $50.
Recap Of Tuesday’s Biotech Catalysts – End Of the Day Summary
The U.S. Food and Drug Administration (FDA) has approved Amphastar’s (NASDAQ:AMPH) New Drug Application (ND”) for Epinephrine injection…
ANI Pharmaceuticals Q1 EPS $(0.12) Misses $0.09 Estimate, Sales $64.50M Miss $65.03M Estimate
ANI Pharmaceuticals (NASDAQ:ANIP) reported quarterly losses of $(0.12) per share which missed the analyst consensus estimate of $0.09 by 233.33 percent. This is a 111.54 percent decrease over earnings of $1.04 per share
Earnings Scheduled For May 10, 2022
Companies Reporting Before The Bell
• The Middleby (NASDAQ:MIDD) is expected to report quarterly earnings at $2.10 per share on revenue of $935.99 million.
68 Biggest Movers From Yesterday
Gainers
Sonim Technologies, Inc. (NASDAQ: SONM) shares jumped 103.3% to settle at $1.22 on Tuesday after the company announced its XP8 smartphone has integrated with the Walkie Talkie in Microsoft Teams.
Mid-Afternoon Market Update: Nasdaq Rises Over 200 Points; ANI Pharmaceuticals Shares Slide
U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining 350 points on Tuesday.
ANI Pharma’s Posts Mixed Bag Q4 Earnings, FY22 Sales Outlook Trails Street Consensus
ANI Pharmaceuticals Inc’s (NASDAQ:ANIP) Q4 revenues were $60.9 million, +6.4% Y/Y, beating the consensus of $56.30 million. Net revenues for…
The Week Ahead In Biotech (March 13-19): Bristol-Myers Squibb’s Melanoma Drug Decision, Multiple Conference Presentations And Earnings Dominate Proceedings
Biotech stocks pulled back for a second week running, as the Ukraine war cast its cloud on the broader market. Dwindling earnings news flow and company-specific developments served as catalysts during the week.